전홍재 (차의과학대학교 분당차병원)님 | 한빛사연구자 > 한빛사

차의과학대학교 분당차병원

CV File

종양의학

최종업데이트 2026.06.10.

[Research Letter] Clinical significance of gross morphological type beyond tumor burden in hepatocellular carcinoma treated with atezolizumab plus bevacizumab
- Clin. Mol. Hepatol., Aug 21 2026, | https://doi.org/10.3350/cmh.2026.0866
- 2026-08
- 의약학
- 한빛사논문
[Correspondence] Correspondence to letter to the editor on "Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features"
- Clin. Mol. Hepatol., Jul 2026, 32 (3) | https://doi.org/10.3350/cmh.2026.0208
- 2026-07
- 의약학
- 한빛사논문
Clinical utility of liquid biopsy in biliary tract cancer: Diagnosis to treatment monitoring
- Clin. Mol. Hepatol., Jun 25 2026, | https://doi.org/10.3350/cmh.2026.0337
- 2026-06
- 의약학
- 한빛사논문
- 전홍재(차의과학대학교 분당차병원)
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma
- J. Hepatol., Jun 15 2026, S0168-8278(26)02605-X | https://doi.org/10.1016/j.jhep.2026.05.018
- 2026-06
- 의약학
- 한빛사논문
A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma
- Clin. Cancer Res., Jun 09 2026, | https://doi.org/10.1158/1078-0432.CCR-26-0273
- 2026-06
- 의약학
- 한빛사논문
Efficacy of nivolumab plus ipilimumab in advanced hepatocellular carcinoma with and without high-risk features: an international multicenter study
- Liver Cancer, March 23 2026 | https://doi.org/10.1159/000551631
- 2026-03
- 의약학
- 한빛사논문
Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer
- Clin. Mol. Hepatol., Dec 26 2025, | https://doi.org/10.3350/cmh.2025.1019
- 2025-12
- 의약학
- 한빛사논문
Biology-driven stratification of advanced biliary tract cancer treated with nab-paclitaxel plus gemcitabine-cisplatin: A prospective observational cohort study
- Hepatology, Dec 19 2025, | https://doi.org/10.1097/HEP.0000000000001650
- 2025-12
- 의약학
- 한빛사논문
Clinical feasibility of ctDNA in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
- Liver Cancer, November 18 2025 | https://doi.org/10.1159/000549565
- 2025-11
- 의약학
- 한빛사논문
Integrative Multi-Omics Profiling Identifies Infiltrative HCC as an Immunotherapy-Resistant Subtype with Distinct Molecular Features
- Clin. Mol. Hepatol., Oct 27 2025, | https://doi.org/10.3350/cmh.2025.0792
- 2025-10
- 의약학
- 한빛사논문

연구자 ID

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기